Finally, clinicians should be aware that in non-AD groups, especially those in which co-existence of AD pathological change is a common finding, such as CBS and DLB, amyloid co-pathology significantly influences plasma p-tau181 and GFAP levels. Here, GFAP is linked to Lewy body dementia.